A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies

2024-511453-22-00 Protocol KQB198-101 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 28 Oct 2024 · Status Ongoing, recruiting · 3 EU/EEA countries · 17 sites · Protocol KQB198-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 162
Countries 3
Sites 17

Participants with Advanced Solid Malignancies

Key facts

Sponsor
Kumquat Biosciences Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
28 Oct 2024 → ongoing
Decision date (initial)
2024-08-29
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-511453-22-00
WHO UTN
U1111-1303-5047

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Participants with Advanced Solid Malignancies

VersionLevelCodeTermSystem organ class
21.0 LLT 10049280 Solid tumour 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Kumquat Biosciences Inc.

Sponsor organisation
Kumquat Biosciences Inc.
Address
10770 Wateridge Circle
City
San Diego
Postcode
92121-5805
Country
United States

Scientific contact point

Organisation
Kumquat Biosciences Inc.
Contact name
Regulatory Submissions

Public contact point

Organisation
Kumquat Biosciences Inc.
Contact name
Regulatory Submissions

Locations

3 EU/EEA countries · 17 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 42 5
Italy Ongoing, recruiting 30 2
Spain Ongoing, recruiting 40 10
Rest of world
Taiwan, United States, Korea, Republic of
50

Investigational sites

France

5 sites · Ongoing, recruiting
Oncopole Claudius Regaud
Oncologie Médical, 1 Avenue Irene Joliot Curie, 31059, Toulouse Cedex 9
Centre Hospitalier Universitaire De Bordeaux
Oncologie Médical, 1 Rue Jean Burguet, 33000, Bordeaux
Centre Hospitalier Universitaire De Nantes
Oncologie thoracique, Boulevard Du Professeur Jacques Monod, 44800, Saint Herblain
Institut De Cancerologie De L Ouest
Oncologie Médical, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex
Institut Paoli Calmettes
Oncologie Médical, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille

Italy

2 sites · Ongoing, recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
U.O.C. Phase 1, Largo Francesco Vito 1, 00168, Rome
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Ricerca Traslazionale a Servizio dei Percorsi Oncologici, Via Mariano Semmola 52, 80131, Naples

Spain

10 sites · Ongoing, recruiting
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid
Clinica Universidad De Navarra
Oncology, Avenue Pio XII 36, 31008, Pamplona
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Quironsalud Barcelona
Oncology, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Hm Nou Delfos
Oncology, Avinguda De Vallcarca 151, 08023, Barcelona
Hospital Quironsalud Malaga
Oncology, Avenida Imperio Argentina 1, 29004, Malaga
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitari Dexeus Grupo Quironsalud
Oncology, Calle De Sabino Arana 5-19, 08028, Barcelona
Hospital Universitario Ramon Y Cajal
Oncology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2025-01-24 2025-03-12
Italy 2024-12-12 2025-03-26
Spain 2024-10-28 2024-11-29

Application history

8 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-13 Spain Acceptable
2024-08-29
2024-08-29
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-09-06 Spain Acceptable
2024-08-29
2024-09-06
3 SUBSTANTIAL MODIFICATION SM-1 2024-09-19 Spain Acceptable 2024-09-26
4 SUBSTANTIAL MODIFICATION SM-2 2025-02-24 Spain Acceptable
2025-05-09
2025-05-09
5 SUBSTANTIAL MODIFICATION SM-3 2025-06-25 Spain Acceptable
2025-08-11
2025-08-12
6 SUBSTANTIAL MODIFICATION SM-4 2025-11-12 Spain Acceptable
2025-12-22
2025-12-23
7 NON SUBSTANTIAL MODIFICATION NSM-2 2026-01-09 Acceptable
2025-12-22
2026-01-09
8 SUBSTANTIAL MODIFICATION SM-5 2026-04-06 Spain Acceptable
2026-05-14
2026-05-18